Mainz Biomed Initiates Feasibility Study for Pancreatic Cancer Blood Test

Mainz Biomed has launched the feasibility phase of its PancAlert project, which aims to develop a non-invasive blood-based screening test for early pancreatic cancer detection. This phase seeks to validate earlier discovery results that demonstrated 95% sensitivity and 98% specificity in detecting pancreatic cancer through a biomarker panel licensed from Liquid Biosciences, using real clinical blood samples analyzed with a machine learning algorithm. The feasibility study, conducted in collaboration with Crown Bioscience, will assess the assay's robustness, reproducibility, and diagnostic accuracy under controlled laboratory conditions, guiding further development and preparation for regulatory submissions such as FDA approval. Alongside PancAlert, Mainz Biomed is advancing its colorectal cancer test, eAArly DETECT 2, with interim data expected by summer 2025. The company’s recent public offering has strengthened its financial position, and analysts maintain a positive outlook with a Buy rating and a price target significantly higher than the current stock price, reflecting optimism about the commercial potential of these cancer diagnostics. Mainz Biomed's mission focuses on addressing unmet needs in oncology by delivering accessible early detection tools for cancers with limited or no current screening options.